Physician profile
Max Levitt
NPI 1487499307
$3,610.54
in general payments reported to CMS, 2019-2025
12 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,366 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223 · Travel and Lodging: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.93 |
| Travel and Lodging | $1,387.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,056.75 | 2024-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $526.76 | 2024-2025 | Lithovue, Spaceoar Vue System - 10ml |
| Calyxo, INC. | $346.55 | 2025 | Cvac Aspiration System |
| Olympus America INC. | $165.01 | 2024-2025 | Itind System |
| Sumitomo Pharma America, INC. | $144.13 | 2025 | Gemtesa |
| Procept Biorobotics Corporation | $111.11 | 2024 | |
| Endo USA, INC. | $106.47 | 2024-2025 | Xiaflex, Aveed |
| 180 Medical, INC. | $48.94 | 2024-2025 | Gentlecath |
| Antares Pharma, INC. | $40.31 | 2024-2025 | Xyosted |
| Urogen Pharma, INC. | $25.83 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.82 | 2025 | |
| Janssen Biotech, INC. | $16.86 | 2025 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.